NCT04017195 - A Study of New Transdermal Contraceptive Patch at End of Shelf Life and Currently Marketed EVRA at the Beginning of Shelf Life in Healthy Women | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 12, 2019

Primary Completion Date

December 13, 2019

Study Completion Date

December 13, 2019

Conditions

Healthy

Interventions

DRUG

EVRA patch (NGMN+EE) (Treatment A) (Reference)

A single transdermal contraceptive patch of EVRA (NGMN + EE) will be applied to the buttock (right or left) of participants on Day 1 of each Treatment period and is removed 7 days after patch application, that is, on Day 8.

DRUG

High molecular weight polyisobutylene (HMW PIB) patch (NGMN+EE) (Treatment B) (Test)

A single transdermal contraceptive HMW PIB (NGMN + EE) patch will be applied to the buttock (right or left) of participants on Day 1 of each Treatment period and is removed 7 days after patch application, that is, on Day 8.

Trial Locations (3)

2060

SGS Belgium NV, Antwerp

10117

Charite - Universitaetsmedizin Berlin (CCM), Berlin

9728 NZ

PRA Health Sciences Onderzoekscentrum Groningen, locatie Martini, Groningen

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY